Recombinant Human HLA-A*0201 NY-ESO-1 complex Protein (C-10His) | PKSH034036

Recombinant Human HLA-A*0201 NY-ESO-1 complex Protein (C-10His) | PKSH034036 | Gentaur US, UK & Europe Disrtribition

Synonyms: MHC; MY-ESO-1; HLA-A*0201 NY-ESO-1 complex Protein

Active Protein: N/A

Activity: Recombinant Human HLA-A*0201 NY-ESO-1 complex Protein is produced by our Mammalian expression system and the target gene encoding (SLLMWITQC)&Ile21-Met119&Gly25-Ile308 (Ala269Val) is expressed with a 10His tag at the C-terminus.

Protein Construction: Recombinant Human HLA-A*0201 NY-ESO-1 complex Protein is produced by our Mammalian expression system and the target gene encoding (SLLMWITQC)&Ile21-Met119&Gly25-Ile308 (Ala269Val) is expressed with a 10His tag at the C-terminus.

Fusion Tag: C-10His

Species: Human

Expressed Host: Human Cells

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 90 % as determined by reducing SDS-PAGE.

Endotoxin: < 1.0 EU per µg as determined by the LAL method.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 49.1 kDa

Formulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 500mM NaCl, pH7.4.

Reconstitution: Please refer to the printed manual for detailed information.

Background: NY-ESO-1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. Optimally assembled peptide-HLA-B2M trimer translocates to the surface of antigen-presenting cells, where it interacts with TCR and CD8 coreceptor on the surface of T cells.

Research Area: Microbiology, immunology, Cardiovascular, Cancer